Literature DB >> 15577672

Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases.

Semra Olgac1, Madhu Mazumdar, Guido Dalbagni, Victor E Reuter.   

Abstract

Urothelial carcinomas of the renal pelvis are relatively rare tumors, and large series that include clinicopathologic and outcome data are few. We reviewed 130 consecutive nephroureterectomies performed for urothelial carcinoma of the renal pelvis at our institution. Tumors were graded using the World Health Organization/International Society of Urologic Pathologists (WHO/ISUP) grading system and were staged according to the 2002 TNM classification; 83 (63.6%) of the patients were men and 47 (36.4%) were women. The mean age at diagnosis was 67 years (range, 41-93 years). The average tumor size was 3.7 cm; 36 of the cases were multifocal and 5 were bilateral. Lower tract disease occurred in 50.7% (66 cases); 38 of the cases (29.3%) were low grade and the remaining 92 (70.7%) were high grade. A total of 50% of the cases were pTis, pTa, or pT1, while 45% invaded deeply (pT2 or more). Depth of invasion could not be assessed with certainty in 7 cases (5%). Regional lymph nodes were identified/submitted in only 50 cases. Of those, 12 cases (24%) had lymph node metastasis. Follow-up information was available in 125 (96%) patients. The period of follow-up ranged from 1 week to 176 months (mean, 48.9 months). At last follow-up, 47 patients (36%) had died of other causes, 18 (13.8%) were dead of disease, 8 patients (6%) were alive with disease, and 52 patients (40%) were alive with no evidence of disease. In univariate analysis, histologic grade (P = 0.001), TNM stage (P = 0.0001), vascular invasion (P = 0.001), margin status (P = 0.021), and size (P = 0.0003) were significantly associated with survival. On multivariate analysis, TNM stage (P = 0.03) was the only variable associated with survival. In conclusion, our study shows that a high percentage of the urothelial carcinoma of the renal pelvis present with locally advanced (pT2 or more) disease at the time of nephroureterectomy. Pathologic stage is the most potent predictor of survival, similar to lower tract disease. A subset of the cases could not be staged due to processing issues; we thus recommend fixation prior to prosecting.

Entities:  

Mesh:

Year:  2004        PMID: 15577672     DOI: 10.1097/00000478-200412000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  32 in total

1.  Genomic Characterization of Upper Tract Urothelial Carcinoma.

Authors:  John P Sfakianos; Eugene K Cha; Gopa Iyer; Sasinya N Scott; Emily C Zabor; Ronak H Shah; Qinghu Ren; Aditya Bagrodia; Philip H Kim; A Ari Hakimi; Irina Ostrovnaya; Ricardo Ramirez; Aphrothiti J Hanrahan; Neil B Desai; Arony Sun; Patrizia Pinciroli; Jonathan E Rosenberg; Guido Dalbagni; Nikolaus Schultz; Dean F Bajorin; Victor E Reuter; Michael F Berger; Bernard H Bochner; Hikmat A Al-Ahmadie; David B Solit; Jonathan A Coleman
Journal:  Eur Urol       Date:  2015-08-14       Impact factor: 20.096

2.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

3.  Upper urinary tract urothelial carcinoma with intratubular spread.

Authors:  Judy Sarungbam; Boaz Kurtis; John Phillips; Dongming Cai; David Zhang; Islam Humayun; Ximing Yang; Minghao Zhong
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

4.  Diffusion-weighted MRI as a potential imaging biomarker reflecting the metastatic potential of upper urinary tract cancer.

Authors:  Y Uchida; S Yoshida; S Kobayashi; F Koga; J Ishioka; S Satoh; C Ishii; H Tanaka; Y Matsuoka; N Numao; K Saito; H Masuda; Y Fujii; K Kihara
Journal:  Br J Radiol       Date:  2014-07-30       Impact factor: 3.039

5.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

6.  HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.

Authors:  Yuka Sasaki; Takeshi Sasaki; Taketo Kawai; Teppei Morikawa; Keisuke Matsusaka; Akiko Kunita; Haruki Kume; Ichiro Aoki; Yukio Homma; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report.

Authors:  Soichiro Yoshida; Shuichiro Kobayashi; Fumitaka Koga; Junichiro Ishioka; Chikako Ishii; Hiroshi Tanaka; Yasukazu Nakanishi; Yoh Matsuoka; Noboru Numao; Kazutaka Saito; Hitoshi Masuda; Yasuhisa Fujii; Kazunori Kihara
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

8.  Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.

Authors:  Laleh Ehsani; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  Endoscopic management of upper tract urothelial carcinoma.

Authors:  K Moore; J Khastgir; M Ghei
Journal:  Adv Urol       Date:  2009-01-04

10.  Conservative management of upper tract transitional cell carcinoma.

Authors:  Markian R Iwaszko; Amy E Krambeck
Journal:  Indian J Urol       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.